Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population

Wu, Bingcao; Li, Sophia S; Song, Ji Young; Pericone, Christopher D.; Behl, Ajay S.; Dawson, Nancy A.

doi:10.1080/13696998.2019.1678171

Cited by 16 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, our cost estimates for nmCRPC are lower than those provided in previously published cost studies (25)(26)(27). The greatest difference can be noticed with respect to US-based studies, while our results are more in line with those provided in the Swedish study (especially when considering the whole range of estimates).…”

Section: Discussionsupporting

confidence: 49%

“…Based on the analysis of electronic health records from January 2007 to August 2017, the authors found that the mean yearly cost per patient (in 2016 US dollars) amounts to $ 15,969 (€ 14,434) before nmCRPC diagnosis and $ 32,935 (€ 29,770) after nmCRPC diagnosis. Wu et al (26) conducted a retrospective cohort analysis of patients with nmCRPC who progressed to mCRPC, selected from insurance claims data in the United States, and estimated all-cause healthcare costs (including hospitalizations, ER visits, office and outpatient visits, use of skilled nursing facilities, and pharmacy costs). The mean yearly cost per patient (in 2016 US dollars) for nmCRPC patients was estimated between $27,549 (€ 24,902) and $29,192 (€ 26,387).…”

Section: Discussionmentioning

confidence: 99%

“…The first is a more methodological one, as whilst asking clinicians to provide their opinion, we thought that limiting their estimates of resource consumption over a clearly predefined (1-year) time horizon facilitated their answers and the inter-expert comparability. The second is more practical, as this is the time horizon also used by other studies which estimated healthcare costs of nmCRPC (always reporting the per-patientper-year cost) (25)(26)(27).…”

Section: Expert Elicitation and Coi Analysismentioning

confidence: 99%

See 2 more Smart Citations

Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy

Borsoi

Ciani

Fornarini

et al. 2023

Int J Technol Assess Health Care

View full text Add to dashboard Cite

Objectives The management of non-metastatic castration-resistant prostate cancer (nmCRPC) is rapidly evolving; however, little is known about the direct healthcare costs of nmCRPC. We aimed to estimate the cost-of-illness (COI) of nmCRPC from the Italian National Health Service perspective. Methods Structured, individual qualitative interviews were carried out with clinical experts to identify what healthcare resources are consumed in clinical practice. To collect quantitative estimates of healthcare resource consumption, a structured expert elicitation was performed with clinical experts using a modified version of a previously validated interactive Excel-based tool, EXPLICIT (EXPert eLICItation Tool). For each parameter, experts were asked to provide the lowest, highest, and most likely value. Deterministic and probabilistic sensitivity analyses (PSA) were carried out to test the robustness of the results. Results Ten clinical experts were interviewed, and six of them participated in the expert elicitation exercise. According to the most likely estimate, the yearly cost per nmCRPC patient is €4,710 (range, €2,243 to €8,243). Diagnostic imaging (i.e., number/type of PET scans performed) had the highest impact on cost. The PSA showed a 50 percent chance for the yearly cost per nmCRPC patient to be within €5,048 using a triangular distribution for parameters, and similar results were found using a beta-PERT distribution. Conclusions This study estimated the direct healthcare costs of nmCRPC in Italy based on a mixed-methods approach. Delaying metastases may be a reasonable goal also from an economic standpoint. These findings can inform decision-making about treatments at the juncture between non-metastatic and metastatic prostate cancer disease.

show abstract

Section: Discussionsupporting

confidence: 49%

Section: Discussionmentioning

confidence: 99%

Section: Expert Elicitation and Coi Analysismentioning

confidence: 99%

See 1 more Smart Citation

Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy

Borsoi

Ciani

Fornarini

et al. 2023

Int J Technol Assess Health Care

View full text Add to dashboard Cite

show abstract

“…A previous study of oral targeted therapies found that both AA and ENZ precipitated greater all-cause healthcare costs than older agents, namely docetaxel and prednisone [ 60 ]. Numerous other cost-effectiveness analyses have corroborated this finding.…”

Section: Discussionmentioning

confidence: 99%

“…Direct healthcare costs of castration-resistant PCa range from USD 2474 to USD 67,957 annually. These costs increase five-fold upon metastasis, and HRU increases 1.5–2.5-fold [ 60 ]. Given the significant cost and healthcare need, it is important to assign treatments which minimize healthcare burdens at the patient and systems-based levels.…”

Section: Discussionmentioning

confidence: 99%

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review

Shah

Shaver

Beiriger

et al. 2022

Cancers

View full text Add to dashboard Cite

Abiraterone acetate (AA) and enzalutamide (ENZ) are commonly used for metastatic prostate cancer. It is unclear how their outcomes and toxicities vary with patient-specific factors because clinical trials typically exclude patients with significant comorbidities. This study aims to fill this knowledge gap and facilitate informed treatment decision making. A registered protocol utilizing PRISMA scoping review methodology was utilized to identify real-world studies. Of 433 non-duplicated publications, 23 were selected by three independent reviewers. ENZ offered a faster and more frequent biochemical response (30–50% vs. 70–75%), slowed progression (HR 0.66; 95% CI 0.50–0.88), and improved overall survival versus AA. ENZ was associated with more fatigue and neurological adverse effects. Conversely, AA increased risk of cardiovascular- (HR 1.82; 95% CI 1.09–3.05) and heart failure-related (HR 2.88; 95% CI 1.09–7.63) hospitalizations. Ultimately, AA was associated with increased length of hospital stay, emergency department visits, and hospitalizations (HR 1.26; 95% CI 1.04–1.53). Accordingly, total costs were higher for AA, although pharmacy costs alone were higher for ENZ. Existing data suggest that AA and ENZ have important differences in outcomes including toxicities, response, disease progression, and survival. Additionally, adherence, healthcare utilization, and costs differ. Further investigation is warranted to inform treatment decisions which optimize patient outcomes.

show abstract

Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial—Prostate Cancer Secondary Screening in Sapienza (PROSA)

et al. 2023

View full text Add to dashboard Cite

Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population

Cited by 16 publications

References 19 publications

Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy

Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review

Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial—Prostate Cancer Secondary Screening in Sapienza (PROSA)

Contact Info

Product

Resources

About